Netherlands-based Royal DSM acquired the flavour and fragrance bio-based intermediates business of California-based Amyris in order to extend the Dutch corporation’s presence in bio-based flavour and fragrance ingredients. The transaction was completed on 31 March 2021 for an initial payment of USD 150 m. DSM and Amyris will continue their R&D partnership.

Since 2017, these two companies have worked together closely. DSM has already acquired Amyris’ Farnesene – a sugarcane-based chemical reputed for its calming effects – business and licensed it to Givaudan, and has purchased its Brotas (Brazil) biotechnology manufacturing facilities where DSM produces several of Amyris’ flavour products.

Now, this most recent acquisition more tightly ties these two companies together as this agreement comes with the transfer of seven of Amyris’ intermediate products. Four of these products are already generating “meaningful sales,” according to DSM. Two other products recently launched and one is still under development. Amyris will continue to share in the sales growth of products that are just launched or under development until 2024.

According to the Dutch science company, this acquisition strengthens its foundation in biotechnology activities in nutritional ingredients, broadens the company’s portfolio in aroma ingredients, and strengthens its sustainability profile, since these bio-based ingredients provide an alternative to chemical-based products.